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Background: Treatment burden refers to the workload imposed by healthcare on patients, and the effect this has
on quality of life. The Treatment Burden Questionnaire (TBQ) aims to assess treatment burden in different condition
and treatment contexts. Here, we aimed to evaluate the validity and reliability of an English version of the TBQ, a
scale that was originally developed in French.
Methods: The TBQ was translated into English by a forward-backward translation method. Wording and possible
missing items were assessed during a pretest involving 200 patients with chronic conditions. Measurement
properties of the instrument were assessed online with a patient network, using the PatientsLikeMe website.
Dimensional structure of the questionnaire was assessed by factor analysis. Construct validity was assessed by
associating TBQ global score wıth clinical variables, adherence to medication assessed by Morisky’s Medication
Adherence Scale (MMAS-8), quality of life (QOL) assessed by the PatientsLikeMe Quality of Life Scale (PLMQOL),
and patients’ confidence in their knowledge of their conditions and treatments. Reliability was determined by a
test–retest method.
Results: In total, 610 patients with chronic conditions, mainly from the USA, UK, Canada, Australia, or New Zealand,
completed the TBQ between September and October 2013. The English TBQ showed a unidimensional structure
with Cronbach α of 0.90. The TBQ global score was negatively correlated with the PLMQOL score (rs = −0.50;
p < 0.0001). Low rather than moderate or high adherence to medication was associated with high TBQ score
(mean [SD] TBQ score 61.8 [30.5] vs. 37.7 [27.5]; P < 0.0001). The treatment burden was higher for patients who had
insufficient knowledge compared with those who had sufficient knowledge about their treatments (mean ± SD TBQ
score 62.3 ± 31.3 vs. 47.8 ± 30.4; P < 0.0001) and conditions (63.0 ± 31.6 vs. 49.3 ± 30.7; P < 0.0001). The intraclass
correlation coefficient for the retest (n = 282) was 0.77 (95% CI 0.70 to 0.82).
Conclusions: We found that the English TBQ is a reliable instrument in this population, and provide evidence
supporting the construct validity for its use to assess treatment burden for patients with one or more chronic
conditions in English-speaking countries.
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Treatment burden is defined as the ‘work’ of being a
patient and its effect on the quality of life (QOL) of
patients. It represents the challenges associated with
everything patients have to do to take care of themselves
(e.g. medication intake, drug management, self-monitoring,
visits to the physician, laboratory tests, lifestyle changes,
administrative tasks to access and coordinate care) [1-3].
This work can represent a tremendous investment of
time, attention, cognitive energy, and effort. For example,
a patient with a chronic condition may spend 2 hours or
more per day on health-related activities [4], and this in-
creases for patients with multiple chronic conditions who
receive treatment or recommendations for each of their
diseases [5,6]. For these patients, treatment burden could
be considered a crucial outcome for disease management
[7]. Difficulties with their treatment are often not shared
in depth by patients during medical consultations [8], and
physicians are often not aware of the challenges their
patients face in coping with everything asked of them
[9]. Thus, a tool that is simple to understand and easy
to administer is needed to identify overburdened pa-
tients in daily practice and for research, in order to de-
sign new therapeutic strategies that are both efficient
and acceptable for patients.
The Treatment Burden Questionnaire (TBQ) is the only
existing instrument that measures treatment burden with-
out restricting its scope to a single condition or treatment
context [9,10]. The TBQ is composed of 13 items rated
on a Likert scale ranging from 0 (not a problem), to 10
(big problem). The TBQ was derived from a literature
review and qualitative semi-structured interviews with
patients in France. It assesses the burden associated with
taking medicine, self-monitoring, laboratory tests, doctor
visits, need for organization, administrative tasks, following
advice on diet and physical activity, and social impact of the
treatment. Item scores can be summed into a global score,
ranging from 0 to 130. The instrument was first developed
with a sample of patients with one or more chronic con-
ditions, who were recruited from hospitals and general-
practice clinics in France.
To measure treatment burden in English-speaking
countries, the TBQ needs to be adapted: items must re-
main comprehensible without changing their original
meaning, and it should be recognized that new items
could arise in different contexts whereas some existing
items might be irrelevant. Patients must be involved in
the process to ensure that the resulting tool is clear
and relevant [11].
In this study, we aimed to assess the validity and reli-
ability of an English version of the TBQ intended to be
used in both routine practice and in research for patients
with at least one chronic condition living in the USA,
Canada, UK, Australia, or New Zealand.Methods
Adaptation and validation of the TBQ in English followed
a multi-step approach recommended in the literature
[12-14]: 1) review the conceptual evidence about treatment
burden in English-speaking countries; 2) translate the
TBQ into English; 3) pretest the instrument with patients
to assess the relevance of items, clarity and wording and;
4) assess validity and reliability by a test–retest of the
adapted instrument.
Conceptual evidence of treatment burden in
English-speaking countries
During a literature review of MEDLINE via Pubmed, we
identified several articles describing the concept of treat-
ment burden in English-speaking countries. In the USA,
Eton and colleagues identified three broad themes for
treatment burden: 1) work patients must do to take care
of their health, 2) problem-focused strategies to facilitate
self-care, and 3) factors that exacerbate the perceived bur-
den [2]. In the UK, Gallacher and associates found four
similar themes in patients with chronic heart failure and
stroke: 1) learning about treatments and their conse-
quences, 2) engaging with others, 3) adhering to treatment
and lifestyle changes, and 4) monitoring their treatments
[15,16]. Finally, in Australia, Sav and associates identi-
fied four inter-related components of treatment burden:
1) financial, 2) time and travel, 3) medication, and 4)
healthcare access burdens [17].
The original TBQ encompassed all of these domains,
with the exception of the financial treatment burden,
because in France, the public health insurance program
guarantees healthcare free of charge for patients with
chronic conditions. Therefore, we added a new item in the
English adaptation of the TBQ: ‘How would you rate the fi-
nancial burden associated with your healthcare (e.g., out-of-
pocket expenses or expenses not covered by insurance)?’
Translation of the TBQ into English
Translation of the TBQ intoEnglish involved a classic
‘forward-backward’ translation method [13]. First, the ori-
ginal instrument in French was translated into English by
two bilingual translators; one (CB) had a medical back-
ground, and was familiar with the concept of treatment bur-
den. Second, the two obtained translations were synthesized
and reviewed by a committee, which included the authors
of the original questionnaire. Third, two different transla-
tors, blinded to the original version, back-translated the
questionnaire into French. Finally, the committee reviewed
and synthesized all translations to elaborate English items
that were similar to the original items and easy to answer.
Pre-testing the instrument
To assess the relevance of items, clarity, and wording,
we pre-tested the obtained instrument with a convenience
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file 1). We used an internet platform, the Open Re-
search Exchange (ORE) [18,19], to recruit patients on
PatientsLikeMe (PLM) [20], an online network where
200,000 voluntary participants with chronic conditions
share data about their treatment, conditions, and symp-
toms. Members of PLM join the site with the expectation
that they will be participating in research. To participate,
patients had to have at least one chronic condition (defined
as requiring ongoing healthcare for at least 6 months). After
having answered the questionnaire, they provided feedback
about 1) the clarity, wording, and relevance of the items,
and 2) any burden that they felt was not covered or insuffi-
ciently covered in the questionnaire in an open-ended man-
ner. Their answers were categorized and discussed by two
of the authors (VT-T and CB).
Concerning the wording of items, 10 patients (5.0%)
felt that the word ‘constraints’ was confusing, thus we
replaced the word ‘constraints’ by the word ‘problem’,
as suggested by the patients. Patients were also asked
whether there were any important elements of treat-
ment burden that they considered to be missing from
questions: 15 patients (7.5%) thought that relationships
between patients and healthcare providers were insuf-
ficiently covered in the original items. Other suggestions
were either specific to a particular condition, were related
to the burden of disease, or were already covered in the
existing items. Thus, we added a new item for testing:
‘How would you rate the difficulties you could have in
your relationships with healthcare providers (e.g., feeling
not listened to enough or not taken seriously)?’ After the
pretest, the English TBQ was therefore composed of 15
items, with rating scales ranging from 0 to 10 and labeled
anchors (‘not a problem’ and ‘large problem’).
Assessment of validity and reliability of the English TBQ
We studied the measurement properties of the instrument
by 1) describing the item properties, 2) assessing factor
structure, 3) assessing construct validity, and 4) assessing
reliability by test–retest.
We recruited a convenience sample of patients via the
aforementioned internet platform. Patients were eligible
if they were 18 years or older, and had at least one con-
dition that had required ongoing health care for at least
6 months. We sent email invitations to a random sample
of 3,000 members on the internet platform who did not
participate in the pretest and who met the eligibility cri-
teria, encouraging them to connect to the website and
complete the questionnaire. To increase the number of
respondents, an email reminder was sent after 2 months.
Patients consented electronically to participate in the
study. The recruitment message outlined the purpose of
the study and reminded patients that they were under
no obligation to participate, that their aggregated resultsmay be published. Because there were no anticipated
adverse consequences for participation, institutional review
board (IRB) approval was not sought for this project.
Item properties were described using three criteria: 1) pro-
portion of missing answers, 2) relevance of items assessed by
the proportion of ‘does not apply,’ and 3) score distributions.
Factor structure was investigated by exploratory factorial
analysis. Scree plots were used to visualize a break between
factors with large eigenvalues and those with smaller eigen-
values. Factors that appeared before the horizontal break
were assumed to be meaningful. Internal consistency was
assessed by Cronbach’s α [21], and was considered accept-
able between 0.70 and 0.95 [22].
The global score of the TBQ (TBQ Global score) was the
sum of the answers to each item. ‘Does not apply’ or missing
answers were considered the lowest possible score (0) be-
cause we considered that a patient not concerned by a do-
main of treatment burden had no burden for that domain.
Construct validity was tested by confirming four
pre-specified hypotheses. First, we expected a negative
correlation between treatment burden (as measured
by the TBQ global score) by the TBQ global score) and
quality of life. Quality of life was measured by the
PatientsLikeMe Quality of Life (PLMQOL) scale, a
validated 24-item questionnaire assessing physical,
mental, and social quality of life. PLMQOL scores
range from 0 to 100 for each domain (higher scores in-
dicating better quality of life) and are summed for a
global assessment of quality of life [23]. Second, we
predicted an association between TBQ global score and
adherence to medication: the greater the treatment
burden, the lower the adherence to treatment. Adher-
ence to medical treatment was measured by Morisky’s
Medication Adherence Scale 8 (MMAS-8) [24,25], a vali-
dated eight-item questionnaire, with scores ranging from
0 to 8. High adherence is a score of 8; medium adher-
ence, 6 to 7; and low adherence, less than 6 [24]. Third,
we hypothesized that patients with better knowledge of
their conditions and treatments would have a low treat-
ment burden. Confidence in patients’ knowledge about
their treatments and conditions was assessed by two
questions: ‘Do you think you have sufficient knowledge
about your conditions (e.g., symptoms, disease progres-
sion)?’ and ‘Do you think you have sufficient knowledge
about your treatments (e.g., possible side effects, expected
benefits, other treatment options)?’. Answers were rated on
a five-step scale: ‘very sufficient’, ‘sufficient’, ‘average’, ‘insuffi-
cient’ and ‘very insufficient’. Finally, we assumed a posi-
tive correlation between TBQ global score and the
following clinical variables: 1) number of conditions,
2) drug administration (number of tablets, injections,
and administrations per day), and 3) medical follow-up
(number of different physicians, medical appointments
per month, and hospitalizations per year).
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the patient to self identify the condition(s) from a list
recommended as core for any measure of multimorbid-
ity [26]. Options were presented as categories illustrated
by common conditions; for example: ‘Rheumatologic
disease (e.g. osteoporosis, arthritis, or inflammatory
polyarthropathies)’. Patients were encouraged to complete
their answer with free text. The text was analyzed, and the
condition was categorized in the appropriate category by a
single investigator (VTT).
The association between the TBQ global score, quality of
life score and clinical variables was assessed by Spearman
correlation coefficient (rs), which was considered high
when greater 0.50, and moderate when 0.35 to 0.50 [27].
Wilcoxon and Kruskal-Wallis tests were used to compare
qualitative variables across groups. P < 0.05 was considered
statistically significant.
Reliability of the instrument was determined by a test–
retest method. Patients were asked to complete the new
instrument twice: at baseline and again after 2 weeks when
they received an email reminder. Reliability was assessed
by the intraclass correlation coefficient (ICC) for agree-
ment [28], defined as the ratio of the subject variance by
the sum of the subject variance, the rater variance and the
residual. The 95% confidence interval (CI) was determined
by a bootstrap method. Agreement was considered accept-
able when ICC was greater than 0.60 [29]. Agreement was
represented by Bland and Altman plots, which represent
the differences between two measurements against the
means of the two measurements [30].
Statistical analyses were performed using SAS (version
9.3; SAS Inst., Cary, NC, USA) and R (version 3.0 [31], the
R Foundation for Statistical Computing, Vienna, Austria).
Results
In total, 3,000 patients were invited to complete the TBQ,
and 610 (20.3%) did so between September and October
2013. The mean ± SD age was 51.5 ± 2.4 years. Patients
resided mainly in the USA (57.5%), Canada (8.4%), UK
(8.7%), and Australia/New Zealand (3.4%). Some patients
(13.3%) lived in other countries (Belgium, Brazil, Chile,
Czech Republic, Denmark, Finland, France, Germany,
India, Ireland, Israel, Italy, Malaysia, Norway, Oman,
Portugal, Russia, South Africa, Spain, Switzerland, Ukraine,
and Uzbekistan), or the country of residence was missing
(8.7%). The mean ± SD number of chronic conditions was
2.9 ± 1.9 (range 1 to 11) (Table 1).
We found a high completion rate (>99%) for all items.
All items were relevant for all patients, with the proportion
of ‘does not apply’ ranging from 0.6% to 7.2%, with the
exception of the burden associated with self-monitoring
(30.3%) (see Additional file 2). The TBQ global score was
the sum of the answers to each of the 15 items, and ranged
from 0 to 150 (‘Does not apply’ was considered the lowestpossible score). The global score had a high correlation
with the score for each item of the TBQ (rs = 0.47 to 0.71)
(see Additional file 3).
Factor structure, assessed by scree plots, favored a
unidimensional instrument. The first factor explained
87% of the variance, and had an eigenvalue of 5.91.
For subsequent factors, eigenvalues wereless than 0.80
(see Additional file 4).
Construct validity showed a significant moderate negative
correlation between the TBQ global score and PLMQOL
score (rs =−0.50; P < 0.0001). Correlation coefficients ranged
from rs = −0.39 (P < 0.0001) for physical quality of life to
rs = −0.50 (P < 0.0001) for mental quality of life, indicating
that patients with high TBQ score had low quality of life
(Table 2). We found a significant association between
treatment burden measured by the TBQ global score and
adherence to medication measured by the MMAS-8:
mean ± SD TBQ global score was 37.7 ± 27.5 for patients
with high or moderate adherence, and 61.8 ± 30.5 for pa-
tients with low adherence (P < 0.0001) (Table 2). The TBQ
score was also significantly associated with patients’ confi-
dence in their knowledge about their treatments and con-
ditions. The mean ± SD TBQ global score was 47.8 ± 30.4
for patients who felt that they had sufficient knowledge
about their treatment, versus 62.3 ± 31.3 for those who felt
that they had insufficient knowledge (P < 0.0001). The
mean ± SD TBQ global score was 49.3 ± 30.7 for patients
declaring sufficient knowledge about their conditions
versus 63.0 ± 31.6 for those with insufficient knowledge
(P < 0.0001) (Table 2). Finally, we found a low to moderate
significant positive correlation of TBQ score with clinical
variables in terms of number of different conditions, drug
administrations (number of tablets, injections, and admin-
istrations per day) and medical follow-up (number of
different physicians, medical appointments per month,
and hospitalizations per year) (see Additional file 5).
Reliability was assessed by a test–retest method for 282
patients (46%). Participants in the retest showed similar
characteristics as patients in the test phase (Table 1). For
the TBQ global score, the ICC for agreement was 0.77
(95% CI 0.70 to 0.82) (see Additional file 6). Bland and
Altman plots for the global TBQ score showed a mean
difference of −0.58; 95% limits of agreement −43.5 and
42.3 (Figure 1).
Subgroup analysis showed a high TBQ global score for
patients who needed equipment such as wheelchairs or
canes (mean ± SD score 69.0 ± 33.4), those who received
physical therapy (62.7 ± 33.9), and those who had gastro-
intestinal (65.4 ± 32.5) or skin (64.9 ± 30.8) diseases (see
Additional file 7). TBQ scores did not differ for the most
common healthcare location (public hospital, private hos-
pital, general practice, or specialist clinic) (P = 0.97).
Overall, treatment burden scores were homogeneous
and comparable between countries. The lowest mean (SD)
Table 1 Demographic and clinical characteristics of
patients in the validation study (n = 610) and retest of
the Treatment Burden Questionnaire (TBQ) for an





Age, yearsa 51.5 ± 12.4 52.3 ± 12.3
Female sex, n (%) 451 (76.7) 215 (76.2)
Country of residence, n (%)
USA 351 (57.5) 172 (61.0)
Canada 51 (8.4) 20 (7.1)
UK 53 (8.7) 26 (9.2)
Australia/New Zealand 21 (3.4) 10 (3.5)
Other/missing 134 (22.0) 54 (19.1)
Educational level, n(%)
Less than High School 24 (3.9) 10 (3.5)
High school graduate or
General Education Diploma
99 (16.2) 55 (19.5)
Some College 220 (36.1) 95 (33.7)
Bachelor’s degree 134 (22.0) 60 (21.3)
Graduate degree 124 (20.3) 58 (20.6)
Treatments, n
Tablets and pills/day 8.5 ± 6.4 8.6 ± 6.7
Injections/week 1.4 ± 4.6 1.5 ± 4.1
Drug administrations/day 3.0 ± 2.0 2.9 ± 1.9
Different doctors the patient sees 3.0 ± 2.3 2.9 ± 1.5
Appointments/month 2.9 ± 2.9 2.7 ± 2.7
Hospitalizations/year 0.5 ± 1.7 0.5 ± 1.1
Presence of an informal caregiver, n (%) 280 (45.9) 125 (44.3)
Most common location for
medical consultations, n (%)
Public hospital 63 (10.3) 30 (10.6)
Private hospital 20 (3.3) 4 (1.4)
General practice clinic 291 (47.7) 135 (47.9)
Specialist clinic 224 (36.7) 106 (37.6)
Duration of oldest chronic
condition, years, n (%)
<5 182 (29.8) 75 (26.6)
5 to 10 217 (35.6) 108 (38.3)
> 10 205 (33.6) 96 (34.0)
Chronic conditions, n 2.9 ± 1.9 2.9 ± 1.9
Conditions, n (%)b
Neurologic disease 277 (45.4) 134 (47.5)
Psychiatric disease 250 (41.0) 107 (37.9)
Rheumatologic disease 203 (33.3) 89 (31.6)
High blood pressure 156 (25.6) 62 (22.0)
Gastrointestinal disease 129 (21.1) 67 (23.7)
Endocrine disorder (other than diabetes) 121 (19.8) 53 (18.8)
Table 1 Demographic and clinical characteristics of
patients in the validation study (n = 610) and retest of
the Treatment Burden Questionnaire (TBQ) for an
English-speaking population (n = 282) (Continued)
Lung disease 93 (15.2) 45 (16.0)
Vision problems 83 (13.6) 35 (12.4)
Fibromyalgia 79 (12.9) 30 (10.6)
Skin disease 71 (11.6) 33 (11.7)
Hearing problem 49 (8.0) 27 (9.6)
Diabetes 45 (7.4) 19 (6.7)
Kidney disease 38 (6.2) 12 (4.2)
Heart disease 34 (5.6) 14 (5.0)
Cancer or malignant blood disease 31 (5.1) 19 (6.7)
Infectious disease 19 (3.1) 10 (3.5)
Stroke or cerebrovascular disease 17 (2.8) 8 (2.8)
aData are mean ± SD unless otherwise indicated.
bAny given patient can have multiple conditions.
Table 2 Association of adherence to medication, patients’
evaluation of their knowledge about their treatment and








Adherence to treatment assessed
by the MMAS-8a
High and moderate adherence 37.7 ± 27.5 – <0.0001




Sufficient 47.8 ± 30.4 – <0.0001
Insufficient 62.3 ± 31.3 – <0.0001
Their conditionsb
Sufficient 49.3 ± 30.7 – <0.0001
Insufficient 63.0 ± 31.6 – <0.0001
Quality of life assessed
by the PLMQOLc
Physical QOL − −0.39 <0.0001
Mental QOL − −0.50 <0.0001
Social QOL − −0.49 <0.0001
Overall assessment of QOL − −0.50 <0.0001
PLMQOL, PatientsLikeMe Quality of Life; QOL, quality of life; TBQ, Treatment
Burden Questionnaire.
aHigh adherence is a score of 8; medium adherence, 6 to 7; and low
adherence, <6 [24]. b‘Very sufficient’ and ‘sufficient’ was considered sufficient
and ‘average’, ‘insufficient’ and ‘very insufficient’was considered insufficient.
cPLMQOL assesses physical, mental and social QOL; high scores indicate better
QOL, while negative correlation coefficients indicate that patients with high
treatment burden have low QOL.
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Figure 1 Bland and Altman plot of the test–retest reliability of the TBQ global score (n = 280).
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0.6 ± 1.1 in Canada to 1.7 ± 2.8 in Australia/New Zealand)
and the highest was for the item related to the effect of
healthcare on relationships with others (from 4.0 ± 3.5 in
Canada to 6.7 ± 3.8 for Australia/New Zealand) (Figure 2).
Discussion
We adapted the TBQ for patients with one or more
chronic conditions living in the USA, Canada, the UK,
Australia, or New Zealand. This is the first valid and
reliable instrument assessing treatment burden across
multiple conditions and treatments.
During the adaptation process, we added two new items
to the English TBQ that did not exist in the original study,
which took place in France [9]. First, we added an item
about the financial treatment burden. In France, the
national health program guarantees healthcare free of
charge for patients with chronic conditions. However,
in countries where the English TBQ was administered,
this is not always the case [10,17]. For example, 30% to
47% of patients in the USA may have problems paying
medical bills [32]. Second, during the pretest, patients
expressed difficulties that they had in their relationships
with healthcare providers. This item was not included
in the original French questionnaire because the au-
thors felt that it measured a concept different from
treatment burden. However, it was mentioned in sub-
sequent qualitative studies [2,15,16] and, in the presentstudy, participants insisted on including this item to
take into account how discussion with physicians could
affect how much they knew about their conditions and
treatment, and how non-optimal relationships with
healthcare providers could hinder adherence to treat-
ment, lifestyle changes, or follow-up. During the first
study, patients may have felt hindered in mentioning
this issue to the investigators during face-to-face inter-
views and therefore the point was underestimated. Use
of a web-based questionnaire has shown a decrease in
socially desirable responses, and an increase in willingness
to disclose sensitive information [33].
Our results highlight the advantages of using an internet
platform: we were able to include 200 patients with chronic
conditions from different countries in the pretest in less
than 1 month. Therefore, we gathered rich qualitative data
on questionnaire items and possible missing concepts,
indicating the high content validity of our tool.
The item properties of the English TBQ were comparable
with those from the original study in France with 1) a
significant floor effect (>15%) for all items, which reflects
that patients could have no burden in the aspects of their
care that they have already integrated into their lives, and
2) about 30% of ‘Does not apply’ for the item related to
self-monitoring. As for the original questionnaire in French,
we chose to keep the item about self-monitoring because
it was considered a mandatory item for other patients,















The taste, shape or size of your tablets and/or the annoyances caused by your injections (e.g., pain, bleeding, bruising or 
scars)
2,6 ± 3.0 3,5 ± 2.9 1,9 ± 2.7 3 ± 3.1 2,1 ± 2.9
The number of times you should take your medication daily 2,4  ± 2.5 3.0 ± 2.8 2,7 ± 2.9 1,4 ± 1.7 2,2 ± 2.6
The efforts you make not to forget to take your medications (e.g., managing your treatment when you are away from home, 
preparing and using pillboxes)
2,9  ± 2.9 4.0 ± 3.2 2,7 ± 2.6 2,6 ± 2.7 2,4 ± 2.9
The necessary precautions when taking your medication (e.g., taking them at specific times of the day or meals, not being able 
to do certain things after taking medications such as driving or lying down)
3,2  ± 3.1 4,2 ± 3.1 3.0 ± 2.9 2,9 ± 3.1 2,7 ± 3.2
Lab tests and other exams (e.g., blood tests or radiology): frequency, time spent and associated nuisances or inconveniences 3,1  ± 3.0 3.0 ± 2.9 1,9 ± 2.5 3,2 ± 3.3 2,7 ± 2.8
Self-monitoring (e.g., taking your blood pressure or checking your blood sugar): frequency, time spent and associated nuisances 
or inconveniences
1,4  ± 2.5 1.0  ± 2.1 0,6 ± 1.1 1,7 ± 2.8 1,6 ± 2.5
Doctor visits and other appointments: frequency and time spent for these visits and difficulties finding healthcare providers 3,9  ± 3.3 3,8 ± 3.2 2,9 ± 3.1 4,1 ± 3.4 3,3 ± 3.2
The difficulties you could have in your relationships with healthcare providers (e.g., feeling not listened to enough or not 
taken seriously)
3,7  ± 3.5 5,4 ± 3.8 3,6 ± 3.5 3,6 ± 3.5 3,5 ± 3.5
Arranging medical appointments and/or transportation (doctors visits, lab tests and other exams) and reorganizing your 
schedule around these appointments
3,8  ± 3.4 4,4 ± 3.4 2,6 ± 2.6 4,2 ± 3.5 2,9 ± 3.0
The administrative burden related to healthcare (e.g., all you have to do for hospitalizations, insurance reimbursements and/or 
obtaining social services)
3,8 ± 3.4 2,8 ± 3.4 2,1 ± 2.5 3,8 ± 3.4 2,8 ± 3.1
The financial burden associated with your healthcare (e.g., out-of-pocket expenses or expenses not covered by insurance) 5,6  ± 3.6 4.0 ± 3.9 3,8 ± 3.6 5,1 ± 3.7 4 ± 3.7
The burden related to dietary changes (e.g., avoiding certain foods or alcohol, having to quit smoking) 3,1 ± 3.3 4.0  ± 3.6 3,3 ± 3.4 3,8 ± 4.0 3,6 ± 3.6
The burden related to doctors' recommendations to practice physical activity (e.g., walking, jogging, swimming) 3,7 ± 3.4 4,6 ± 3.8 3,1 ± 3.2 4,3 ± 3.7 3,2 ± 3.6
How does your healthcare impact your relationships with others (e.g., being dependent on others and feeling like a burden to 
them, being embarrassed to take your medications in public)
4,9 ± 3.7 5,7 ± 3.7 4 ± 3.5 6,7 ± 3.8 4,1 ± 3.4
'The need for medical healthcare on a regular basis reminds me of my health problems’ 6,1 ± 3.6 5,2 ± 3.8 5,3 ± 3.7 6,4 ± 3.4 5,4 ± 3.5
Item scores are presented as mean (SD). Highest scores are in red and lowest in green. *Other includes Belgium, Brazil, Chile, Czech Republic, Denmark, 
Finland, France, Germany, India, Ireland, Israel, Italy, Malaysia, Norway, Oman, Portugal, Russia, South Africa, Spain, Switzerland, Ukraine, Uzbekistan.
**Participants with missing country of residence (n=81) were excluded from the analysis
Figure 2 Comparison of scores for TBQ items by country (n = 529)a.
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countries with different conditions and treatments. As hy-
pothesized, we highlighted statistically significant associa-
tions between the overall treatment burden and adherence
to medication, patients’ confidence in their knowledge
about their conditions and treatment, and quality of life. To
our knowledge, this is the first study to report such associa-
tions independent of disease or treatment contexts. Devel-
opment of interventions to improve patient knowledge
about therapeutic options could lead to shared decision
making, reduced treatment burden,better adherence to
medication, and better quality of life for patients.
We compared TBQ scores between countries and found
that most item scores were homogeneous for patients
in the USA, UK, Canada, and Australia/New Zealand,
with two exceptions. First, we found increased financial
treatment burden for patients residing in the USA and
Australia. This result was expected because qualitative
studies in these countries described the financial burden
as one of the issues most widely discussed by patients
[10,17]. Second, in the UK, we found increased treat-
ment burden related to patients’ relationships with their
healthcare providers. This finding could be related to
pay-for-performance initiatives (for example, Quality and
Outcomes Framework) that may encourage physicians to
focus on biomedical objectives and spend less time listen-
ing to patients’ non-medical problems. More research isneeded to understand the precise aspects of treatment
burden, and why patients might experience different
aspects in each of these countries.
This study has several limitations. First, to measure
patients' confidence in their knowledge about their
treatments and conditions, we used questions that
were not validated. However, participants reviewed
these questions during the pretest in the same way they
reviewed the questions of the TBQ. Patients expressed
no difficulties in answering these questions, and we
found neither any missing answers, nor a floor or ceil-
ing effect. Second, we recruited patients through the
PLM website only, and from this patient group, only
20% of the invited patients responded to the web sur-
vey. This response rate was similar to that from other
studies involving online surveys. This recruitment
method might have selected patients willing to share
their experiences with others and/or with severe or
rare conditions. We did not include participants who
were not able to access a computer. Therefore, our sample
is not representative of the general population of patients
with one or more chronic conditions: overall patients in
our study were younger, more educated, and more often
female (similar to other studies involving the PLM website
[34-36]). Prevalence of chronic conditions in our study
differed from those of chronic conditions of patients seek-
ing healthcare in national surveys. For example, we found
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because PLM was initially developed for these patients.
Although these biases were considered relatively small,
psychometric properties for the TBQ (especially reliability
estimates) might differ in other populations. Despite these
limitations, use of an online platform has a number of
advantages. First, we were able to involve a larger number
of patients than in usual cross-cultural adaptation studies
(800 participants including pretest) [37] in a very short
time (2 months from pretest to results). Second, the re-
cruited patients were geographically dispersed and thus,
we might have avoided selecting only patients living near
research centers. Finally, patients involved were engaged
in research, and therefore provided us with rich feedback
at every stage of our research, which may have contrib-
uted to the development of questionnaire items closer to
patients’ own words and problems.
The present study advances the evidence of the validity
of the TBQ. Further studies should focus on testing other
psychometric properties such as responsiveness in longitu-
dinal and prospective studies. The TBQ can be imple-
mented in clinical trials assessing interventions intended to
mitigate treatment burden and its negative effect on quality
of life to develop a Minimally Disruptive Medicine [1].
Conclusions
We adapted and validated the TBQ for English-speaking
countries (USA, UK, Canada, and Australia) using an
online patient-based platform for direct interaction with
patients. This study resulted in the first instrument asses-
sing treatment burdenfor any condition and treatment
context in these countries.
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